NCT06686108 is a Phase 2 clinical trial of Azacitidine (AZA) Days 1 - 5 in T-cell Acute Lymphoblastic Leukemia, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT06686108?

Interventions in NCT06686108: Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax.

What condition does NCT06686108 study?

NCT06686108 studies T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse.

Is NCT06686108 still recruiting?

NCT06686108 is currently recruiting now. Last updated 7 May 2025.

Last reviewed 2025-05-07 · How we verify

NCT06686108

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Recruiting now Phase 2 Last updated 7 May 2025

What this trial tests

Phase 2 trial testing Azacitidine (AZA) Days 1 - 5 in T-cell Acute Lymphoblastic Leukemia in 59 participants. Currently enrolling.

Timeline

30 October 2024

Primary endpoint
30 October 2027

30 October 2028

Quick facts

Lead sponsor	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	59
Start date	30 October 2024
Primary completion	30 October 2027
Estimated completion	30 October 2028
Sites	1 location across China

Drugs / interventions tested

Azacitidine (AZA) Days 1 - 5 — full drug profile →
Decitabine (DAC) — full drug profile →
Venetoclax (venetoclax) — full drug profile →

Conditions studied

T-cell Acute Lymphoblastic Leukemia — all drugs for T-cell Acute Lymphoblastic Leukemia →
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION — all drugs for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION →
Relapse — all drugs for Relapse →

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

Adults 14 to 55, any sex, with T-cell Acute Lymphoblastic Leukemia or ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, phase II clinical trial with the primary objective of assessing the effectiveness of demethylating agents combined with venetoclax in the prevention of recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) of high risk T-lymphoblastic lymphoma/leukemia (T-LBL/ALL) patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.
Rankin AW, Keating AK, Abu-Arja RF, Thakar MS, et al · · 2026 · PMID 41716469 · DOI 10.1016/j.omton.2026.201141
The use of venetoclax in the treatment of acute lymphoblastic leukemia-a systematic review.
Kowalczyk A, Zarychta J, Zawitkowska J, Lejman M. · · 2026 · PMID 41523908 · DOI 10.1177/17588359251403912

Verify or expand the search:

Other trials of Azacitidine (AZA) Days 1 - 5

Trials testing the same drug.

NCT02269280 — Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) · Phase 2 · completed

Other recruiting trials for T-cell Acute Lymphoblastic Leukemia

Currently open trials in the same condition.

NCT06561074 — A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Ad · Phase 2 · recruiting
NCT06514794 — A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lym · Phase 2 · recruiting
NCT06420076 — Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using · Phase 1, PHASE2 · recruiting
NCT06316427 — Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies · Phase 1, PHASE2 · recruiting
NCT05995028 — Universal 4SCAR7U Targeting CD7-positive Malignancies · Phase 1 · recruiting

Other Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT06667466 — New Laser and Suction Sheath for Kidney Stone Treatment · not yet recruiting
NCT07043374 — Impact of Humid-Heat on Gut-Tryptophan-Stone Pathway · not yet recruiting
NCT07415226 — Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes · not yet recruiting
NCT07469046 — VAH vs VA in Newly Diagnosed Elderly AML · Phase 3 · not yet recruiting
NCT07439120 — Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06686108 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Last refreshed: 7 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06686108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing